Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology generated $18.7 million in Q1 revenue from its recently launched AVMAPKI FAKZYNJA CO-PACK, marking its first commercial sales following FDA approval. The company initiated three Phase 2 registration-directed trials for VS-7375 in pancreatic, lung, and colorectal cancers, accelerating its pipeline development.
Key figures
- Revenue
- 18671000
- Revenue Yoy
- 0
- Rd expenses
- 38218000
- Sga expenses
- 22299000
- Operating expenses
- 63568000
- Cash equivalents and investments
- 181678000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.